The selenium and vitamin E cancer prevention trial

Eric A. Klein, Scott M. Lippman, Ian M. Thompson, Phyllis J. Goodman, Demetrius Albanes, Philip R. Taylor, Charles Coltman

Research output: Contribution to journalReview articlepeer-review

87 Scopus citations


Background: Evidence suggests that both selenium and vitamin E reduce the risk of prostate cancer. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a randomized, prospective, double-blind study designed to determine whether selenium and vitamin E alone and in combination can reduce the risk of prostate cancer among healthy men. Materials and methods: The preclinical and epidemiological evidence supporting a role for selenium and vitamin E as chemopreventive agents in prostate cancer are reviewed, and details of the trial design are presented. Results: Preclinical, epidemiological, and phase III data from randomized, placebo-controlled clinical trials suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. SELECT is a 2×2 factorial study with an accrual goal of 32,400 men with nonsuspicious DRE and serum PSA of 4 ng/ml or lower. Conclusions: SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001 with final results anticipated in 2013.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalWorld Journal of Urology
Issue number1
StatePublished - May 1 2003


  • Chemoprevention
  • Prostate cancer
  • Selenium
  • Vitamin E

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'The selenium and vitamin E cancer prevention trial'. Together they form a unique fingerprint.

Cite this